Steba biotech is a private biotechnology company that is dedicated to the development of solutions to fight cancer.
Steba biotech participates in research into localised prostate cancer, oesophagus cancer, urothelial carcinoma, kidney cancer, pancreatic cancer and triple-negative breast cancer in collaboration with the Memorial Sloan-Kettering Cancer Center (USA), the Weizmann Institute (Israel) and the University of Oxford (United Kingdom).
Innovations in focal therapies – offering therapeutic alternatives in oncology for solid tumours – have been recognised and supported by stakeholders worldwide in urology, radiology and oncology areas at Oxford and Harvard Universities, the Memorial Sloan-Kettering Cancer Center and other medical centres and research institutes.Read more
Steba biotech conducts a research program in different indications, including: prostate cancer at different stages, oesophagus cancer, upper urinary tract cancer, breast cancer and pancreatic cancer.
Steba biotech is studying potential innovations in different solid tumours, such as: